Joint disease is a common lameness cause and a primary reason why many horses’ athletic careers end.
An understanding of how the biology of aging affects the older horse has become increasingly important.
The change comes several months after the FDA approved a pergolide mesylate tablet for use in horses.
A new FDA-approved Pergolide product offers options in the management of clinical signs associated with pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s disease.
A reader is concerned about her 24-year-old easy keeper’s weight loss and sudden difficulty keeping weight on.
The objective of the survey is to determine the prevalence of Cushing’s disease worldwide.
Patella infections in foals, while uncommon, can result in prolonged and severe stifle joint infection.
Season variations in ACTH levels are found in some geographic areas, while no changes take place in others.
The study will test a novel neutriceutical for the treatment of lameness in horses due to osteoarthritis.
“Cushing’s Disease and Equine Metabolic Syndrome” was presented by three authorities on the topics.
Three veterinarians discuss the challenges of properly diagnosing and treating/managing horses afflicted with equine Cushing’s disease, equine metabolic syndrome, and associated laminitis.
Endocrinopathic laminitis might be more common in horses affected by endocrine disease than once believed.
The newly approved medication is the first and only FDA-approved product for managing PPID in horses.
A green-lipped mussel-derived product could be useful for combating some signs of osteoarthritis in horses.
The Arabian Horse Foundation released summaries of the research projects the organization funded in 2011.
What is the difference between these three potentially confusing conditions?
Stay on top of the most recent Horse Health news with
